Literature DB >> 29285507

Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world.

Richard J MacIsaac1,2, Elif I Ekinci3,4.   

Abstract

Entities:  

Year:  2017        PMID： 29285507      PMCID： PMC5733328          DOI： 10.21037/atm.2017.10.11

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  18 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Effect of sodium-glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with Type 2 diabetes.

Authors:  T Sato; T Miki; H Ohnishi; T Yamashita; A Takada; T Yano; M Tanno; A Tsuchida; T Miura
Journal:  Diabet Med       Date:  2017-08-03       Impact factor: 4.359

3.  Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2.

Authors:  Vance B Matthews; Rosemary H Elliot; Caroline Rudnicka; Jana Hricova; Lakshini Herat; Markus P Schlaich
Journal:  J Hypertens       Date:  2017-10       Impact factor: 4.844

4.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

5.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

6.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

Authors:  John J V McMurray; Hertzel C Gerstein; Rury R Holman; Marc A Pfeffer
Journal:  Lancet Diabetes Endocrinol       Date:  2014-03-13       Impact factor: 32.069

Review 7.  SGLT2 inhibitors in the treatment of type 2 diabetes.

Authors:  Farhad M Hasan; Mazen Alsahli; John E Gerich
Journal:  Diabetes Res Clin Pract       Date:  2014-03-11       Impact factor: 5.602

8.  CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

Authors:  Ele Ferrannini; Michael Mark; Eric Mayoux
Journal:  Diabetes Care       Date:  2016-07       Impact factor: 19.112

9.  Heart failure prevalence, incidence, and mortality in the elderly with diabetes.

Authors:  Alain G Bertoni; W Gregory Hundley; Mark W Massing; Denise E Bonds; Gregory L Burke; David C Goff
Journal:  Diabetes Care       Date:  2004-03       Impact factor: 19.112

10.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Authors:  Mikhail Kosiborod; Matthew A Cavender; Alex Z Fu; John P Wilding; Kamlesh Khunti; Reinhard W Holl; Anna Norhammar; Kåre I Birkeland; Marit Eika Jørgensen; Marcus Thuresson; Niki Arya; Johan Bodegård; Niklas Hammar; Peter Fenici
Journal:  Circulation       Date:  2017-05-18       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.